Presenting the Future Home of Tevogen Bio

Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly global headquarters in New Jersey. This facility will serve as the company’s central hub for research and development, manufacturing, and distribution of its investigational T cell therapies for COVID-19, other viral infections and oncology. The 160-thousand square foot facility will bring nearly 1,800 life sciences jobs to New Jersey, leveraging the state’s rich history and support structure for medical innovation. The headquarters will be powered, in part, by renewable energy based on solar and other environmentally-friendly technologies. Congratulations to our team of visionary architects and lab engineers!

Latest News

Tevogen Bio™ to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

Businesswire – January 20th, 2022

Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Businesswire – January 12th, 2022

Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council

Businesswire – January 5th, 2022

Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19

Businesswire – December 29th, 2021

Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021

Businesswire – December 14th, 2021

Tevogen Bio Announces U.S. Patent and Trademark Office Has Granted Patent for Preparation of Tevogen’s SARS-CoV-2 Specific Allogeneic Cytotoxic T Lymphocytes (CTL) and Methods of Treatment Using Tevogen’s Investigational CTL Therapy for COVID-19

Businesswire – December 8th, 2021

Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council

Businesswire – December 6th, 2021

SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19

Yale School of Public Health – December 6th, 2021

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Businesswire – December 2nd, 2021

FDA OK’s next phase for Jefferson University’s new COVID-19 treatment

6ABC News – November 29th, 2021

SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced

Yale School of Public Health – November 22nd, 2021

Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients

Businesswire – November 16th, 2021

Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council

Businesswire – October 27th, 2021

A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System

Yale School of Public Health – October 8th, 2021

Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy

Businesswire – September 9th, 2021

Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

Businesswire – September 1st, 2021

Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model

Pharma Tech Outlook – August 30th, 2021

Tevogen Bio Partners with Yale School of Public Health to Prepare Tomorrow’s Leaders in Regulatory Science

Businesswire – July 14th, 2021

Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Businesswire – July 12th, 2021

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Businesswire – May 11th, 2021

Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Businesswire – April 12th, 2021

Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.

Cell & Gene – March 23rd, 2021

Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Businesswire – March 15th, 2021

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Newswire – January 25th, 2021

Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

Newswire – October 14th, 2020

Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.

6ABC – August 20th, 2020

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza

Newswire – August 10th, 2020

Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Newswire – July 15th, 2020

Social Media

© 2021 Tevogen Bio. All Rights Reserved.